Leadership Overview
Eisai Global has 8 executives leading key functions including corporate strategy, information technology, regional market development, and pharmaceutical research.
Committed to a human health care philosophy, Eisai Global advances patient-centered medicine through rigorous research and development across global markets to improve health outcomes.
Committed to a human health care philosophy, Eisai Global advances patient-centered medicine through rigorous research and development across global markets to improve health outcomes.
Leadership Roles at Eisai Global
Tatsuyuki Yasuno - Chairman & Chief Executive Officer & Eisai Inc Region President (Americas)
Tatsuyuki Yasuno, the Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) at Eisai Global, directs the overarching corporate strategy and pharmaceutical manufacturing operations across the North American market. Yasuno architects the long-term vision for human health care, ensuring that all research initiatives align with the company's mission to address unmet patient needs. By overseeing the integration of regional business units, the Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) maintains operational excellence and drives growth within the competitive pharmaceutical landscape. This leadership role involves constant collaboration with the Board to refine global development pipelines. Through the implementation of patient-centered healthcare solutions, Tatsuyuki Yasuno secures the company's market position. Ultimately, Yasuno fosters a culture of innovation that supports the delivery of high-quality medicines to diverse patient populations throughout the Americas.
Hiroyuki Murayama - President (Japan) & Promotion Department Manager, Product Strategy
Hiroyuki Murayama, the President (Japan) & Promotion Department Manager, Product Strategy at Eisai Global, oversees domestic pharmaceutical operations and the strategic promotion of core medical products. Murayama architects comprehensive market strategies that emphasize the human health care approach, ensuring that product positioning resonates with healthcare providers and patients alike. By managing the product strategy department, the President (Japan) & Promotion Department Manager, Product Strategy coordinates cross-functional teams to maximize the impact of new therapeutic launches. This leadership role involves analyzing market trends to refine promotional activities and maintain strong brand presence. Through the execution of targeted outreach programs, Hiroyuki Murayama drives revenue growth and strengthens the company's reputation within the Japanese market. Ultimately, Murayama ensures that all promotional efforts remain strictly aligned with the company's commitment to patient-centered healthcare delivery.
Yanhui Feng - President & General Manager (Eci)
Yanhui Feng, the President & General Manager (Eci) at Eisai Global, directs all business operations and market expansion efforts within the China region. Feng architects localized strategies that adapt the company's global pharmaceutical portfolio to meet specific regional healthcare requirements. By overseeing the entire supply chain and distribution network, the President & General Manager (Eci) ensures that essential medicines reach patients efficiently across diverse geographic territories. This leadership role involves navigating complex regulatory environments while maintaining high standards of manufacturing quality. Through the cultivation of strategic partnerships with local healthcare institutions, Yanhui Feng expands the company's footprint and enhances access to innovative treatments. Ultimately, Feng drives sustainable growth by aligning regional operational goals with the broader corporate mission of providing comprehensive healthcare solutions to the Chinese population.
Kazuhiko Tamura - Vice President and President, Eisai Demand Chain Systems
Kazuhiko Tamura, the Vice President and President, Eisai Demand Chain Systems at Eisai Global, manages the end-to-end logistics and supply chain architecture for pharmaceutical products. Tamura architects robust demand planning systems that synchronize manufacturing output with global market requirements, minimizing waste and ensuring product availability. By optimizing the flow of goods from production facilities to end-users, the Vice President and President, Eisai Demand Chain Systems maintains operational agility in a volatile global market. This leadership role involves integrating advanced forecasting tools to anticipate shifts in demand and adjust production schedules accordingly. Through the implementation of lean supply chain practices, Kazuhiko Tamura improves cost efficiency and supports the company's overall financial health. Ultimately, Tamura ensures that the supply chain remains a reliable backbone for the company's commitment to consistent patient care.
Toshimitsu Uenaka - President, Epochal Precision Anti-Cancer Therapeutics
Toshimitsu Uenaka, the President, Epochal Precision Anti-Cancer Therapeutics at Eisai Global, leads the specialized research and development unit focused on oncology. Uenaka architects the scientific roadmap for precision medicine, ensuring that the company remains at the forefront of anti-cancer therapeutic innovation. By overseeing clinical trials and laboratory research, the President, Epochal Precision Anti-Cancer Therapeutics drives the development of targeted treatments that address specific genetic markers in cancer patients. This leadership role involves collaborating with global research teams to accelerate the transition from discovery to commercialization. Through the application of cutting-edge biotechnology, Toshimitsu Uenaka enhances the efficacy of the company's oncology portfolio. Ultimately, Uenaka secures the company's position as a leader in the oncology sector by delivering breakthrough therapies that significantly improve patient survival rates and quality of life.
Kenichi Nomoto - President, Oncology Product Creation Unit
Kenichi Nomoto, the President, Oncology Product Creation Unit at Eisai Global, manages the lifecycle of oncology products from initial concept to final market release. Nomoto architects the product creation strategy, ensuring that new therapeutic candidates meet rigorous safety and efficacy standards before entering the market. By coordinating with cross-functional teams, the President, Oncology Product Creation Unit streamlines the development process and reduces time-to-market for critical cancer medications. This leadership role involves evaluating the commercial viability of new compounds and aligning development efforts with global oncology market needs. Through the management of complex product portfolios, Kenichi Nomoto ensures that the company maintains a robust pipeline of innovative treatments. Ultimately, Nomoto supports the company's mission by transforming scientific discoveries into tangible healthcare solutions that address the urgent needs of cancer patients worldwide.
Michael Montaigne - President, Eisai Machinery (USA)
Michael Montaigne, the President, Eisai Machinery (USA) at Eisai Global, directs the manufacturing technology and machinery division within the United States. Montaigne architects the operational strategy for producing high-precision pharmaceutical equipment, ensuring that all machinery meets the stringent quality requirements of the global manufacturing network. By overseeing the engineering and production teams, the President, Eisai Machinery (USA) maintains the technical standards necessary for efficient pharmaceutical production. This leadership role involves managing client relationships and providing technical support to ensure the seamless integration of machinery into existing production lines. Through the continuous improvement of manufacturing hardware, Michael Montaigne enhances the overall productivity of the company's pharmaceutical operations. Ultimately, Montaigne drives innovation in manufacturing technology, supporting the company's ability to produce high-quality medicines at scale for the global market.
Makoto Hoketsu - Vice President & Chief Information Officer
Makoto Hoketsu, the Vice President & Chief Information Officer at Eisai Global, manages the digital infrastructure and data security frameworks supporting global pharmaceutical manufacturing. Hoketsu designs scalable technology solutions that optimize research and development workflows, ensuring that data integrity remains a priority across all international operations. By modernizing enterprise systems, the Vice President & Chief Information Officer enables seamless communication between global research hubs and manufacturing facilities. This leadership role requires constant alignment with corporate security standards to protect sensitive patient information and proprietary research data. Through the deployment of advanced analytics, Makoto Hoketsu enhances operational efficiency and supports data-driven decision-making processes. Ultimately, Hoketsu provides the technological foundation necessary for the company to maintain a competitive edge in the rapidly evolving digital healthcare sector.
Explore Leadership Teams in Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership CD
NB
ES
SS
Jubilant Pharmova is a patient-focused biopharmaceutical company based in Noida, India.
Company Leadership RF
AR
Tilray was established in 2018 in British Columbia, Canada. They specialize in the research, cultivation, production and distribution of medical cannabis and cannabinoids.
Company Leadership
BM
LB
Tabuk Pharmaceuticals is a generic pharmaceutical company that delivers quality cost-effective prices in the regulated markets of the MENA region. The company provides to the major therapeutic areas of GI and diabetes, cardiovascular, musculoskeletal, respiratory, infection, and the central nervous system pharmaceuticals.
Company Leadership IS
DB
HR
Frequently Asked Questions Regarding Eisai Global Top Executives and Leadership Team
Unlock more people and company data
